MKMesrure Köseoğlu

Mesrure Köseoğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mesrure Köseoğlu has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of cognitive impairments in multiple sclerosis: a comparative analysis of the Rey complex figure test and the symbol digit modalities test

    by Mesrure Köseoğlu, Aslı Yaman Kula, Mehmet Demir, Ebru Temiz, Betül Artun, Zeynep Aksu, Gürkan Yaman, Nazlı Durmaz Çelik, Serkan Özben

    Cognitive impairment is common in multiple sclerosis (MS), and visual memory impairments are increasingly considered clinically important, yet still underappreciated. To compare cognitive performance assessed by the Rey Complex Figure Test (RCFT) and Symbol Digit Modalities Test (SDMT) in MS patients and healthy controls, and to examine correlations between these measures and physical disability indices. A total of 177 participants were assessed using RCFT subtests and SDMT, of whom 95 had relapsing-remitting MS (RRMS) and 82 were healthy controls. Group comparisons and correlation analyses were performed. The MS patients scored significantly lower on all RCFT subtests and SDMT. Moderate correlations were found between SDMT and RCFT 0 to 2, but not RCFT 3. Both RCFT and SDMT may serve as potentially complementary measures of cognitive domains relevant to MS. Incorporating both recall and recognition-based measures, along with processing speed assessments, can provide a broader evaluation of cognitive strengths and weaknesses in MS, helping clinicians better characterize patients' profiles.

  • Association of HLA-DRA, HLA-DQA1, and IL-6 gene variations with susceptibility to multiple sclerosis

    by Gulsah Koc, Aysegul Sahbaz, Busranur Oguz Selcuk, Fusun Mayda Domac, Serkan Demir, Mesrure Koseoglu, Ebru Hatun Uludasdemir, Deniz Kirac

    Background Multiple sclerosis (MS), which can lead to severe physical or cognitive disability and neurological deficits, is a chronic autoimmune disease affecting the central nervous system (CNS). The etiology and pathogenesis of MS remain unclear; nonetheless, it is asserted that its cause is complex, with genetic predisposition playing a significant role. In this study, our aim was to analyze the relationship between MS and HLA-DRA (rs3135388 and rs3135391), HLA-DQA1 (rs9272346) and IL-6 (rs1800795 and rs1900796) gene polymorphisms, which play an important role in inflammation and immune response. Methods The study included 100 healthy controls and 98 MS patients. Real-time polymerase chain reaction (RT-PCR) was used to analyze variations in rs3135388 and rs3135391 in the HLA-DRA gene, rs9272346 in the HLA-DQA1 gene, and rs1800795 and rs1900796 in the IL-6 gene following DNA isolation from peripheral blood. Statistical techniques were applied to assess the outcomes. Results The results showed a significant difference in IL-6 (rs1800796) G/C (p = 0.024) between the patient and control groups when genotypes and allele distributions were analyzed. HLA-DQA1 (rs9272346) and HLA-DRA (rs3135388 and rs3135391) variations did not substantially differ between the two groups. Similarly, no significant difference was found between the two groups in VitD, B12 and folic acid parameters, and there was no relationship between these parameters and genotypes. Conclusion There is evidence suggesting a significant association between IL-6 (rs1800796) polymorphisms and MS. IL-6 (rs1800796) GC genotype may be associated with disease susceptibility or risk. This should be taken into account in association and intervention studies on MS.

  • Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study

    by Meryem Tuba Sönmez, Mehmet Fatih Yetkin, Duygu Arslan Mehdiyev, Mesrure Köseoğlu, Semra Mungan, Nilufer Kale, Murat Terzi, Abdulkadir Tunç, Emine Rabia Koç, Sedat Şen, et al.


  • Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients

    by Aysegul Sahbaz, Busranur Oguz Selcuk, Fusun Mayda Domac, Serkan Demir, Mesrure Koseoglu, Ebru Hatun Uludasdemir, Gulsah Koc, Bayram Yılmaz, Deniz Kirac

    Multiple sclerosis (MS) is among the most common autoimmune disorders and is characterized by inflammation and degeneration affecting the central nervous system. Glatiramer acetate (GA) is an immunomodulatory drug utilized for treating relapsing–remitting MS. However, a considerable number of patients do not exhibit an appropriate response to this drug. This condition is known as GA resistance. This study aimed to investigate the relationship between nucleotide variations in the HLA-DRA, HLA-DQA1 and IL-6 genes and GA resistance. Additionally, the relationship of environmental factors with MS was investigated. One hundred thirty-nine MS patients were enrolled in this study. Patients were divided into two groups: non-responders (n = 58) and responders (n = 81). After DNA was isolated from peripheral blood, the rs3135388 and rs3135391 variations in HLA-DRA, the rs9272346 variation in HLA-DQA1, and the rs1800795 and rs1900796 variations in IL-6 were analyzed by Real-Time Polymerase Chain Reaction (RT-PCR). At the end of the study, it was found that the number of females was approximately 3 times greater in responders and 4 times greater in non-responders than in males. When nucleotide variations and allele distributions were compared between the groups, no significant relationships were found. Similarly, no significant relationship was found between risk factors and nucleotide variations. However, in non-responders, the expanded disability status scale and lesion load were found to be significantly high. In conclusion, by increasing the number of patients, more meaningful results can be achieved in future studies. Elucidating the pharmacogenetic characteristics (the drug–gene relationship) of MS patients using GA could lead to the development of personalized treatment strategies.


  • Open Access

    Effects of positive airway pressure therapy on quality of life in patients with obstructive sleep apnea syndrome

    by Isil Yazici Gencdal, Mesrure Koseoglu, Vasfiye Kabeloglu, Kursat Nuri Baydili

    Objective: Obstructive sleep apnea syndrome (OSAS) significantly impairs the quality of life of affected individuals. This study aimed to assess the health-related quality of life (HRQoL) among patients with mild, moderate, and severe OSAS, and to evaluate differences in HRQoL following a minimum of three months of continuous positive airway pressure (CPAP) therapy. Method: Subjective daytime sleepiness and HRQoL were assessed using standardized questionnaires, including the Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), Apathy Evaluation Scale (AES), and Montgomery-Åsberg Depression Rating Scale (MADRS). Assessments were conducted at the initial visit following an OSAS diagnosis, confirmed through clinical and polysomnographic evaluation. After at least three months of CPAP therapy, the same HRQoL questionnaires were re-administered. The percentage change difference (PCD) for each questionnaire was calculated by comparing baseline scores with those obtained after at least three months of CPAP therapy. Results: A total of 87 patients with OSAS were included in the study. Twenty-seven were female (31%) and 60 were male (69%). Comparison of scale scores before and after CPAP therapy revealed statistically significant reductions across the ESS, BDI, AES, MADRS, and FSS questionnaires (p<0.001). A weak positive correlation was found between the ESS PCD and body mass index, while a moderate negative correlation was observed between the AES PCD and duration of CPAP therapy (p<0.001). Conclusion: Significant improvements in HRQoL were observed following CPAP therapy, regardless of disease severity, gender, presence of comorbid conditions, and smoking status. With the exception of AES scores, these improvements were also independent of the duration of CPAP therapy. Among the HRQoL scales, only AES scores showed a statistically significant reduction after more than six months of CPAP therapy.

  • Antibodies against SARS-CoV-2 in cerebrospinal fluid: Clinical features and laboratory findings of hospitalized patients with neurologic symptoms in the pandemic era

    by Sezin Alpaydin Baslo, Burcu Yuksel, Isil Baytekin, Araz Ceren Incesoy, Eda Salihoglu Kara, Mesrure Koseoglu, Serap Teker, Begum Cengizler, Fatma Betul Oktelik, Aysu Sen, et al.

    Background and purpose – High titers of anti-SARS-CoV-2 immunoglobulin G (IgG) have been reported in cerebrospinal fluid (CSF) samples of patients with COVID-19, but the data are limited. Our purpose is to report the clinical features and CSF findings of patients with neurologic symptoms in the pandemic era, and to discuss the origin and importance of anti-SARS-CoV-2 IgG in CSF. Methods – The data of 100 patients hospitalized in neurology inpatient clinics and tested for anti-SARS-CoV-2 IgG antibodies in CSF samples, between May 2021 and March 2022, were evaluated in a retrospective manner. Demographic features, presence of coronavirus disease 2019 (COVID-19) and/ or COVID-19 history, vaccination, vaccine type, and neurologic diagnoses were noted. CSF and serum anti-SARS-CoV-2 antibody ratio (AR) were assessed using a Euroimmun ELISA assay. CSF cytology, CSF protein level, oligoclonal band, IgG index, and albumin quotient (QAlb) were analyzed and compared between CSF AR positive and negative groups. Results – QAlb and CSF protein levels were higher in the CSF anti-SARS-CoV-2 AR-positive group compared with CSF anti-SARSCoV-2 AR-negative group (p<0.05). IgG index, CSF cytology, and oligoclonal band (OCB) types did not differ between the groups. Seventy-three percent of patients had OCB type-1. CSF anti-SARS-CoV-2 AR was correlated with serum anti-SARS-CoV-2 AR, Qalb, and CSF protein level, as well as COVID-19 and/or COVID-19 history and vaccination. Conclusion – Anti-SARS-CoV-2 antibodies in CSF seem to be related to a past immunization or a pre-existing cross reactive immunity and passive diffusion through a disrupted blood-brain-barrier, but not to an intrathecal antibody synthesis.

  • Open Access

    Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis

    by Işıl Peker, Hacer Eroğlu İçli, Belgin Mutluay, Burcu Yüksel, Zeynep Özdemir, Mesrure Köseoğlu, Aysu Şen, Dilek Ataklı, Aysun Soysal, Musa Öztürk

    Objective: The course of relapsing–remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (CCL11), and macrophage inflammatory protein 3-alpha (CCL20) in RRMS. Methods: Forty-two patients with MS were enrolled, along with 22 controls, 12 of the controls were idiopathic intracranial hypertension (IIH) patients, and 10 of the controls were other neurologic diseases (OND). Chemokine levels were measured using enzyme-linked immunosorbent assay (ELISA) in serum and cerebrospinal fluid (CSF) samples. Results: No significant differences were observed among the groups in serum levels of CXCL13, CCL11, and CCL20 (p = 0.509, p = 0.979, p = 0.169, respectively). CSF CXCL13 levels were significantly higher in the OND group (p = 0.016). A PATH analysis showed CSF CXCL13 was significantly associated with new T2 hyperintense lesions on brain magnetic resonance imaging (p < 0.001), and baseline serum CCL11 levels were associated with EDSS (p = 0.030), implying its potential role in indicating neurodegenerative processes and possible progression risk. Serum CCL20 correlated with EDSS (p = 0.002) and lesion burden (p < 0.001), reflecting disease severity. Conclusions: These findings suggest that CSF CXCL13 could serve as a useful biomarker for predicting active disease in RRMS, while follow-up serum CCL11 may assist in identifying progression. Although these chemokines are not specific to MS, higher levels may signal disease activity, severity, and transition to more progressive stages.


  • Open Access

    Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein

    by Sümeyye Koç, Sedat Şen, Yüksel Terzi, Ferah Kızılay, Serkan Demir, Dürdane Bekar Aksoy, Fatma Kurtuluş, Nuray Bilge, Egemen Idilman, Cihat Uzunköprü, et al.

    Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Multicenter, retrospective, observational study. Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz Mayıs University's Faculty of Medicine were included in the study. Of the 104 patients with anti-MOG-IgG, 56.7% were women and 43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.


  • Open Access

    Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)

    by Meryem Aslı Tuncer, Murat Kürtüncü, Murat Terzi, Uğur Uygunoğlu, Cansu Göncüoğlu, Ayşe Nur Yüceyar, Özgül Ekmekçi, Recai Türkoğlu, Aysun Soysal, Mesrure Köseoğlu, et al.

    Background/aim: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs. Materials and methods: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and after the switch). Data were collected from the MS patients' database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch. Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group. Conclusion: The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.

  • The effect of cognitive performance on self-management behavior of multiple sclerosis patients

    by Hüsnü Efendi, Aysun Ünal, Aylin Akçalı, Bengü Altunan, Ayhan Bingöl, Burcu Altunrende, Mesrure Köseoğlu, Duygu Deringöl, Cihat Uzunköprü, Cansu Eğilmez, et al.